These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 1260747)

  • 1. Potentiation of actinomycin D or adriamycin antitumor activity with DNA.
    Marks TA; Venditti JM
    Cancer Res; 1976 Feb; 36(2 Pt 1):496-504. PubMed ID: 1260747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin.
    Israel M; Modest EJ; Frei E
    Cancer Res; 1975 May; 35(5):1365-8. PubMed ID: 1054622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA breaks in P288 tumor cells in mice after treatment with daunorubicin and adriamycin.
    Schwartz HS
    Res Commun Chem Pathol Pharmacol; 1975 Jan; 10(1):51-64. PubMed ID: 1124321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
    Dawson KM
    Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of host defense merchanisms in the antitumor activity of adriamycin and daunomycin in mice.
    Mantovani A; Polentarutti N; Luini W; Peri G; Spreafico F
    J Natl Cancer Inst; 1979 Jul; 63(1):61-6. PubMed ID: 286835
    [No Abstract]   [Full Text] [Related]  

  • 7. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
    Borden EC; Sidky YA; Hatcher JF; Bryan GT
    Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression.
    Schwartz HS; Grindey GB
    Cancer Res; 1973 Aug; 33(8):1837-44. PubMed ID: 4720795
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of Corynebacterium parvum alone and in combination with adriamycin in experimental tumor systems.
    Houchens DP; Johnson RK; Ovejera A; Gaston MR; Goldin A
    Cancer Treat Rep; 1976 Jul; 60(7):823-8. PubMed ID: 1009517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
    Li LH; DeKoning TF; Wallace TL
    Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
    Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antitumor effect of methylene blue in vivo].
    Lai BT
    Zhonghua Zhong Liu Za Zhi; 1989 Mar; 11(2):98-100. PubMed ID: 2806052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin.
    Giuliani F; Casazza AM; Di Marco A; Savi G
    Cancer Treat Rep; 1981; 65(3-4):267-76. PubMed ID: 6263470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
    Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
    Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
    Fujimoto K; Oka T; Morimoto M
    Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of amidoximes (hydroxyurea analogs) in murine tumor systems.
    Flora KP; van't Riet B; Wampler GL
    Cancer Res; 1978 May; 38(5):1291-5. PubMed ID: 639062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of antitumor action of pyrimidinones in the treatment of B16 melanoma and P388 leukemia.
    Li LH; Wallace TL; Richard KA; Tracey DE
    Cancer Res; 1985 Feb; 45(2):532-8. PubMed ID: 3967227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
    Avery TL; Roberts D
    Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of menogaril alone, and in combination against human mammary cancer models in mice and rats.
    Yoshida M; Fujioka A; Nakano K; Kobunai T; Saito H; Toko T; Takeda S; Unemi N
    Anticancer Res; 1996; 16(3A):1155-9. PubMed ID: 8702227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors.
    Corbett TH; Griswold DP; Mayo JG; Laster WR; Schabel FM
    Cancer Res; 1975 Jun; 35(6):1568-73. PubMed ID: 1131824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.